This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abraham, R. T. Articles by Gibbons, J. J. Search for Related Content PubMed PubMed Citation Articles by Abraham, R. T. Articles by Gibbons, J. J.

The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy

Authors' Affiliation: Department of Oncology Discovery, Wyeth, Pearl River, New York

Requests for reprints: Robert T. Abraham, Department of Oncology Discovery, Wyeth, 401 North Middletown Road, Pearl River, NY 10960. Phone: 845-602-4594; Fax: 845-602-5557; E-mail: Abrahar{at}wyeth.com and James J. Gibbons, Phone: 845-602-3165; Fax: 845-602-5557; E-mail: gibbonj{at}wyeth.com.

The immunosuppressive drug rapamycin played a key role in the functional characterization of mammalian target of rapamycin (mTOR), an unusual protein kinase that coordinates growth factor and nutrient availability with cell growth and proliferation. Several rapamycin-related compounds are now in various stages of clinical development as anticancer agents. This article highlights recent advances in our understanding of the mTOR signaling pathway and the implications of these findings for the clinical application of mTOR inhibitors in cancer patients.

This article has been cited by other articles:

				X. Jiang, H. Kenerson, L. Aicher, R. Miyaoka, J. Eary, J. Bissler, and R. S. Yeung The Tuberous Sclerosis Complex Regulates Trafficking of Glucose Transporters and Glucose Uptake Am. J. Pathol., June 1, 2008; 172(6): 1748 - 1756. [Abstract] [Full Text] [PDF]

				L. H. Wei, H. Su, I. J. Hildebrandt, M. E. Phelps, J. Czernin, and W. A. Weber Changes in Tumor Metabolism as Readout for Mammalian Target of Rapamycin Kinase Inhibition by Rapamycin in Glioblastoma Clin. Cancer Res., June 1, 2008; 14(11): 3416 - 3426. [Abstract] [Full Text] [PDF]

				J. Bellmunt, C. Szczylik, J. Feingold, A. Strahs, and A. Berkenblit Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features Ann. Onc., April 2, 2008; (2008) mdn066v1. [Abstract] [Full Text] [PDF]

				N. Rhodes, D. A. Heerding, D. R. Duckett, D. J. Eberwein, V. B. Knick, T. J. Lansing, R. T. McConnell, T. M. Gilmer, S.-Y. Zhang, K. Robell, et al. Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity Cancer Res., April 1, 2008; 68(7): 2366 - 2374. [Abstract] [Full Text] [PDF]

				S. Sleijfer and E. Wiemer Dose Selection in Phase I Studies: Why We Should Always Go for the Top J. Clin. Oncol., April 1, 2008; 26(10): 1576 - 1578. [Full Text] [PDF]

				B. I. Rini Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin Clin. Cancer Res., March 1, 2008; 14(5): 1286 - 1290. [Full Text] [PDF]

				N. Yeager, C. Brewer, K. Q. Cai, X.-X. Xu, and A. Di Cristofano Mammalian Target of Rapamycin Is the Key Effector of Phosphatidylinositol-3-OH Initiated Proliferative Signals in the Thyroid Follicular Epithelium Cancer Res., January 15, 2008; 68(2): 444 - 449. [Abstract] [Full Text] [PDF]